Advanced BiomedADVB +3.10%12 3-Year ROIIC % is 54.42 as of Jun. 2025. GuruFocus rates ADVB with a GF Score™ of 12/100. The stock has 1 warning sign investors should review. Among 203 Medical Diagnostics & Research companies, Advanced Biomed ranks better than 75.37% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Advanced Biomed's 3-Year ROIIC % for the quarter that ended in Jun. 2025 was 54.42%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Advanced Biomed's 3-Year ROIIC % or its related term are showing as below:
ADVB's 3-Year ROIIC % is ranked better than 75.37% of 203
companies
in the Medical Diagnostics & Research industry
Industry Median: 0.22
vs ADVB: 54.42
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Advanced Biomed 3-Year ROIIC % Related Terms
Advanced Biomed 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Advanced Biomed's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ADVB vs MBAI, XWEL, NDRA: 3-Year ROIIC % Comparison
For the Diagnostics & Research subindustry, Advanced Biomed's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Advanced Biomed 3-Year ROIIC % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Advanced Biomed's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Advanced Biomed's 3-Year ROIIC % falls into.
Advanced Biomed's 3-Year ROIIC % for the quarter that ended in Jun. 2025 is calculated as:
3-Year ROIIC %
=
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( -3.021 (Jun. 2025) - -2.374 (Jun. 2022) )
/
( 0.755 (Jun. 2025) - 1.944 (Jun. 2022) )
=
-0.647
/
-1.189
=
54.42%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Advanced Biomed (ADVB) has a 3-Year ROIIC % of 54.42 as of Jun. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Advanced Biomed and its competitors. According to the industry distribution chart, Advanced Biomed ranks #50 out of 203 companies in the Medical Diagnostics & Research industry, placing it in the top 24.6%.
Is Advanced Biomed's 3-Year ROIIC % too high?
Advanced Biomed's current 3-Year ROIIC % is 54.42. The Medical Diagnostics & Research industry median 3-Year ROIIC % is 0.22. Advanced Biomed's value of 54.42 is 24636.4% above this industry median. Based on the distribution chart, Advanced Biomed ranks #50 out of 203 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Advanced Biomed has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Advanced Biomed's 3-Year ROIIC % compare to MBAI and XWEL?
According to the Medical Diagnostics & Research industry distribution chart, Advanced Biomed ranks #50 out of 203 companies for 3-Year ROIIC %. This places Advanced Biomed in the top 25% of its industry — outperforming the majority of peers. The industry median 3-Year ROIIC % is 0.22. Advanced Biomed's value of 54.42 is 24636.4% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Medical Diagnostics & Research company?
The median 3-Year ROIIC % among Medical Diagnostics & Research companies is 0.22, based on 203 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Advanced Biomed's current 3-Year ROIIC % of 54.42 is 24636.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Advanced Biomed and its competitors. For the Medical Diagnostics & Research industry, the median 3-Year ROIIC % is 0.22 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Advanced Biomed's current 3-Year ROIIC % is 54.42. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Advanced Biomed stock overvalued right now?
Advanced Biomed (ADVB) has a current 3-Year ROIIC % of 54.42. The current 3-Year ROIIC % is 54.42 and 24636.4% above the Medical Diagnostics & Research industry median of 0.22. Advanced Biomed's overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Advanced Biomed (ADVB), the current 3-Year ROIIC % is 54.42 as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Advanced Biomed Inc operates through its subsidiaries and is mainly engaged in the research and development of various original microfluidic biochip technologies and the provision of tumor precision diagnosis and treatment technology applications. Through the joint application of semiconductor technology and biotechnology, it has developed various technologies and testing equipment for early screening and detection, diagnosis and staging, and treatment of cancer. Its devices: A+Pre, AC-1000, A+CellScan, and A+SCDrop, and three corresponding microfluidic biochips, A+Pre Chip and AC-1000 CTC Enrichment Chip, and A+CellScan Chip, are designed to provide rapid and affordable assay products and services to cancer patients.
12GF Score
Get the complete analysis for ADVB
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ADVB has been successfully added to your 
